MediciNova Total Liab Over Time
| MNOV Stock | USD 2.00 0.05 2.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out MediciNova Performance and MediciNova Correlation. MediciNova |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MediciNova. If investors know MediciNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MediciNova listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.16) | Revenue Per Share 0.02 | Return On Assets (0.1) | Return On Equity (0.13) |
The market value of MediciNova is measured differently than its book value, which is the value of MediciNova that is recorded on the company's balance sheet. Investors also form their own opinion of MediciNova's value that differs from its market value or its book value, called intrinsic value, which is MediciNova's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MediciNova's market value can be influenced by many factors that don't directly affect MediciNova's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MediciNova's value and its price as these two are different measures arrived at by different means. Investors typically determine if MediciNova is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MediciNova's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare MediciNova and related stocks such as Aerovate Therapeutics, Adagene, and Acrivon Therapeutics, Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVTE | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 18.1 M | 2.9 M | 8.6 M | 18 M | 12 M |
| ADAG | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 162.9 M | 173.7 M | 33 M | 69.3 M | 45.2 M | 77.3 M |
| ACRV | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 130.4 M | 10.8 M | 17.1 M | 33.8 M |
| RZLT | 10.5 K | 10.5 K | 5.3 M | 997.9 K | 2.2 M | 2.1 M | 2.1 M | 6.5 M | 10.5 M | 3.6 M | 16.5 M | 2.9 M | 7.5 M | 11.7 M | 6.1 M |
| ANTX | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 24.6 M | 112.7 M | 7.2 M | 14 M | 13.3 M |
| MOLN | 61.8 M | 61.8 M | 61.8 M | 61.8 M | 45.5 M | 67.6 M | 48.3 M | 27.7 M | 63.5 M | 50.8 M | 80.3 M | 65.4 M | 27.1 M | 21.9 M | 40.7 M |
| CSBR | 310 K | 12.2 M | 4.1 M | 5.7 M | 4 M | 5.5 M | 7.6 M | 8.1 M | 9 M | 15.4 M | 20.2 M | 26.3 M | 29.7 M | 28 M | 29.4 M |
| ANEB | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 241.6 K | 512.5 K | 1.1 M | 260.6 K | 247.6 K |
| PMVP | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 173.5 M | 6.4 M | 23 M | 24.3 M | 26.5 M | 48.4 M |
| PHVS | 138.8 K | 138.8 K | 138.8 K | 138.8 K | 138.8 K | 138.8 K | 138.8 K | 138.8 K | 481.3 K | 1.9 M | 5.3 M | 7.1 M | 18.5 M | 14.6 M | 7.6 M |
| PEPG | 326 K | 326 K | 326 K | 326 K | 326 K | 326 K | 326 K | 326 K | 326 K | 326 K | 868 K | 10.5 M | 37.8 M | 34.6 M | 18.5 M |
MediciNova and related stocks such as Aerovate Therapeutics, Adagene, and Acrivon Therapeutics, Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| MediciNova | MNOV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.0
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.